ADCs, TKIs, and the Evolving Treatment Landscape in HER2-Altered NSCLC

Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.

EP: 1.An Overview of HER2 Alterations in NSCLC and Implications for Treatment

EP: 2.Biomarker Testing in NSCLC: Best Practices for Personalized Medicine

EP: 3.T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights

Now Viewing

EP: 4.ADCs, TKIs, and the Evolving Treatment Landscape in HER2-Altered NSCLC

• (Rohit asks Levy) Please briefly highlight other trials of note and how the treatment landscape in HER2-altered NSCLC may evolve over time. What might be the positioning of ADCs, TKIs, and other treatment modalities in the treatment landscapes for HER2-mutated and HER2-overexpressing NSCLC?

Recent Videos